Just days after the 2026 midterm elections, biotechnology leaders will gather in Washington, DC, for a timely conversation about what the results mean for the industry—and what comes next.

This BIO Leadership Summit will bring together a select group of biotech executives, policy leaders, and other senior stakeholders for a timely discussion about what the election results may mean for the industry.

The program will move beyond the immediate headlines to examine the political and policy environment ahead, the potential implications for biotechnology and life sciences, and the leadership challenges and opportunities that may emerge as the new Congress takes shape.

Designed as a focused, senior-level convening, the Summit will emphasize candid conversations, differing perspectives, and meaningful engagement among participants.

WHY ATTEND

The days immediately following a major election are filled with analysis. The BIO Leadership Summit is designed to go further.

Attendees will hear from leading political and public-policy voices and explore questions including:

  • What did the 2026 midterm elections tell us about the country and the political environment ahead?
  • How could changes in Washington affect biotechnology and the broader life sciences sector?
  • Where could bipartisan opportunities emerge in an increasingly divided political environment?
  • What should biotechnology leaders be watching as the new Congress takes shape?
  • How can leaders successfully navigate uncertainty while continuing to advance innovation, investment, and patient impact?

WHO SHOULD ATTEND

The BIO Leadership Summit is an invitation-only forum designed for senior leaders whose organizations operate at the intersection of biotechnology, business, policy, and government.

Invited participants include:

  • Biotechnology and life sciences executives
  • Public policy and government affairs leaders
  • Senior leaders from biotechnology and pharmaceutical companies
  • Investors and other leaders in the life sciences ecosystem
  • Executives from organizations supporting the biotechnology industry, including CROs, CDMOs, suppliers, and other strategic partners